2018: Review of Clinical Trials and Data Analytics

Comment

2018: Review of Clinical Trials and Data Analytics

2018 was a big year with respect to big data and analytics. Not just for clinical trials, but the field overall as it relates to the collection of data, the analysis and deep-mining for patterns and the interpretation thereof to inform strategy. Banking and manufacturing are two industries that are particularly adept in the field but health sciences is not far behind.

Comment

Mining PubMed for Clinical Trial Data

1 Comment

Mining PubMed for Clinical Trial Data

Containing over 28 million citations, PubMed offers a treasure trove of data from across the life-sciences. But honing down on what you’re looking for can be challenging. We explore what it has to offer on clinical trials – and how easy is it to find.

1 Comment

The value of clinical trial data in competitive intelligence

1 Comment

The value of clinical trial data in competitive intelligence

Understanding what your competitors are working on and how it effects your business is key across most industries.  The clinical trial arena is no different.   Knowing what trials are starting or in progress along with the details of the protocols from past trials can give your company a leg up.  Learn more about the importance of clinical trial information as part of your competitive intelligence plan in our new blog post!

1 Comment

Clinical trials for Alzheimer’s disease: what next?

1 Comment

Clinical trials for Alzheimer’s disease: what next?

With this seemingly unrelenting bad news, what does the future hold for drug development for Alzheimer's Disease (AD)? This post provides a brief overview of the landscape of trials for AD and why there is optimism that DMDs for this devastating condition will be a case of when they will be developed not if.

1 Comment

The Rituximab Gold Rush Continues

Comment

The Rituximab Gold Rush Continues

The Rutuximab patent period is over, and now clinical trial experimentation of the product is available to all industry players, which is creating a huge activity of new trials with the drug. We analyze the data.

Comment